Shorts

0:33

How Proton Therapy is Revolutionizing Cancer Treatment

4 months ago

Charles Simone, MD

0:41

Why Patient Preference Matters in CLL Treatment

4 months ago

Adam Kittai, MD(+1 more)

1:00

Low ctDNA May Signal Aggressive Tumor in Head and Neck Cancer

4 months ago

Catherine T. Haring, MD

1:03

The Biggest Unmet Needs in Lung Cancer

4 months ago

Adam Schoenfeld, MD

0:34

Talking MRD and ctDNA With Patients

4 months ago

Rutika Mehta, MD, MPH

0:30

Who Should Get Neoadjuvant Therapy in RCC

4 months ago

Naomi Haas, MD

0:30

Don't Believe The Google Prognosis: New Hope For Glioblastoma

4 months ago

Chibawanye Ene, MD, PhD

0:32

Why We Need To Look Outside the Brain to Treat Tumors

4 months ago

Chibawanye Ene, MD, PhD

0:44

Adjuvant Therapy in Non-Clear Cell RCC

4 months ago

Naomi Haas, MD

0:52

The Prognostic Potential of MRD/ctDNA in Metastatic GE Cancer

4 months ago

Rutika Mehta, MD, MPH

0:50

Don't Over-Treat Based on Risk Scores

4 months ago

Rami Komrokji, MD

0:17

Targeted: On Location at Memorial Sloan Kettering Cancer Center

4 months ago

Helena Yu, MD(+2 more)

0:42

Understanding MDS Staging and the Path to Cure

4 months ago

Rami Komrokji, MD

0:49

ctDNA & MRD: Smarter Therapy Decisions in Metastatic GE Cancer

4 months ago

Rutika Mehta, MD, MPH

0:46

Combining CELMoDs and Cell Therapies in Myeloma

4 months ago

Sagar Lonial, MD, FACP

0:49

Balancing Therapy and QOL With MRD Testing in Gastroesophageal Cancer

4 months ago

Rutika Mehta, MD, MPH

0:35

A Mass in the Right-Sided Kidney

5 months ago

Pavlos Msaouel, MD, PhD

0:47

Menin Inhibitors Could Redefine AML Frontline Therapy

5 months ago

Richard Stone, MD

0:42

Setting a New Standard in EGFR+ Lung Cancer

5 months ago

Nicolas Girard, MD, PhD

0:46

Survival With Bispecific Combo Favors Early Use in Myeloma

5 months ago

Roberto Mina, MD

0:33

The Key Test to Confirm RMC Diagnosis is Immunohistochemistry for INI1

5 months ago

Pavlos Msaouel, MD, PhD

0:48

The Need for HRR Mutation Testing in Prostate Cancer

5 months ago

Sandy Srinivas, MD

1:27

Are We Nearing the End of 7+3 Alone in AML?

5 months ago

Richard Stone, MD

0:32

One Analogy Doesn't Work for Every Patient

5 months ago

Sanjay K. Juneja, MD(+1 more)

0:34

Managing Toxicities in Patients on Erdafitinib Therapy

5 months ago

Thomas W. Flaig, MD

0:59

The Power of a Gut Feeling in Cancer Care

5 months ago

Sanjay K. Juneja, MD

0:38

New Frontiers in Urothelial Carcinoma

5 months ago

Thomas W. Flaig, MD

0:32

CLL17 3-Year Update: Who May Benefit From Continuous Therapy?

5 months ago

Nicole Lamanna, MD

1:00

Bringing Clinical Trials Into the Community

5 months ago

Danny Nguyen, MD

0:43

Early-Onset CRC: Thinking Beyond the Tumor

5 months ago

Patrick Boland, MD

Shorts

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

mRNA Vaccine Plus Pembrolizumab Yields RFS, DMFS Benefit in Resectable Melanoma

FDA Grants ETX-19477 Fast Track Designation in BRCA-Mutated Breast Cancer

FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC

FDA Grants Fast Track Designation to Piktor in Endometrial Cancer

How Agentic AI Aims to Streamline Clinical Trial Enrollment